Ginkgo Bioworks Sees Unusually Large Options Volume (NYSE:DNA)

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 19,822 call options on the company. This is an increase of approximately 387% compared to the average daily volume of 4,068 call options.

Insider Transactions at Ginkgo Bioworks

In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 51,169 shares of the stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $1.05, for a total value of $53,727.45. Following the completion of the sale, the insider now directly owns 865,079 shares in the company, valued at $908,332.95. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Mark E. Dmytruk sold 39,569 shares of the company's stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $1.21, for a total value of $47,878.49. Following the transaction, the insider now directly owns 761,737 shares of the company's stock, valued at approximately $921,701.77. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark E. Dmytruk sold 51,169 shares of Ginkgo Bioworks stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $1.05, for a total value of $53,727.45. Following the sale, the insider now directly owns 865,079 shares of the company's stock, valued at approximately $908,332.95. The disclosure for this sale can be found here. Insiders own 15.05% of the company's stock.

Institutional Investors Weigh In On Ginkgo Bioworks

Institutional investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC lifted its holdings in Ginkgo Bioworks by 9.0% during the fourth quarter. ARK Investment Management LLC now owns 198,606,619 shares of the company's stock valued at $335,645,000 after purchasing an additional 16,414,434 shares in the last quarter. Vanguard Group Inc. lifted its stake in Ginkgo Bioworks by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 132,780,095 shares of the company's stock valued at $224,398,000 after buying an additional 463,096 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Ginkgo Bioworks by 15.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 58,746,160 shares of the company's stock worth $106,331,000 after buying an additional 7,958,613 shares during the last quarter. Norges Bank purchased a new stake in Ginkgo Bioworks during the 4th quarter worth approximately $24,967,000. Finally, Lingotto Investment Management LLP raised its holdings in shares of Ginkgo Bioworks by 34.9% during the fourth quarter. Lingotto Investment Management LLP now owns 8,511,301 shares of the company's stock valued at $14,384,000 after acquiring an additional 2,200,000 shares during the last quarter. Institutional investors and hedge funds own 78.63% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group reduced their price target on shares of Ginkgo Bioworks from $1.25 to $1.10 and set a "sell" rating for the company in a research report on Monday, January 22nd. TD Cowen lowered their price target on shares of Ginkgo Bioworks from $7.00 to $3.00 and set an "outperform" rating on the stock in a report on Friday, March 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $2.20.

Ginkgo Bioworks Stock Up 15.1 %

Shares of NYSE:DNA traded up $0.13 during trading on Monday, hitting $0.99. 75,533,170 shares of the stock traded hands, compared to its average volume of 26,344,895. The company has a fifty day moving average price of $1.12 and a two-hundred day moving average price of $1.33. Ginkgo Bioworks has a 52-week low of $0.74 and a 52-week high of $2.55. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -2.11 and a beta of 1.36.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its earnings results on Thursday, February 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Ginkgo Bioworks had a negative return on equity of 48.23% and a negative net margin of 355.08%. The firm had revenue of $34.76 million for the quarter, compared to analysts' expectations of $40.37 million. During the same period in the previous year, the company earned ($0.04) earnings per share. The company's revenue was down 64.6% compared to the same quarter last year. On average, equities research analysts predict that Ginkgo Bioworks will post -0.32 EPS for the current fiscal year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.